high-intensity focused ultrasound

Fusion Bx-guided HIFU shows promise in localized PCaEarly follow-up of men with localized prostate cancer treated with novel technology that integrates fusion biopsy findings to guide high-intensity focused ultrasound (HIFU [Focal One]) shows the technique has promise for minimizing post-treatment morbidity while providing good cancer control, Italian researchers reported at the AUA annual meeting in Boston.
Exploring safety, efficacy of high-intensity focused ultrasound in glaucomaHigh-intensity focused ultrasound cyclocoagulation is safe and effective in most refractory glaucomatous eyes. Complete success was achieved in 80% (24/30) of treated eyes that had undergone the maximum of three procedures.
HIFU results in low morbidity, QoL preservationAnother study suggests that hemiablation with high-intensity focused ultrasound is a promising treatment for unilateral localized prostate cancer.
Prostate HIFU lands in the U.S. Now what?"With all this uncertainty, the good news is that men will no longer need to travel to Canada or elsewhere for prostate HIFU therapy," writes Leonard G. Gomella, MD.
Data offer new insight on HIFU’s use in low-risk PCaTransrectal HIFU shows a statistically significant increase in per-core negative biopsy rates.
Salvage HIFU shows promise in post-RT PCa patientsHigh-intensity focused ultrasound as salvage therapy allows for intermediate-term disease control in selected patients with recurrence following radiation therapy for prostate cancer.
Focal cryo vs. focal HIFU: Similar oncologic outcomesOncologic outcomes are similar using focal cryotherapy and focal high-intensity focused ultrasound for treatment of localized prostate cancer, French urologists reported at the World Congress of Endourology and SWL in London.
FDA clearance of HIFU met with enthusiasm, questionsThe Sonablate 450, SonaCare Medical’s high-intensity focused ultrasound (HIFU) device, has received FDA clearance for prostate tissue ablation.
Best of AUA 2014: Prostate Cancer
Best of AUA 2014: Prostate CancerMichael C. Gong, MD, PhD, presents the take home messages on prostate cancer from the AUA annual meeting in Orlando, FL, including new findings about enzalutamide (XTANDI).
Urologists critical of HIFU on TwitterUrologists on Twitter criticized high-intensity focused ultrasound and in some instances even mocked the treatment.